Rapport

Artificial intelligence in managed care: Trends from 2024 to 2026

Artificial intelligence is moving from early experimentation to more practical application across managed care. In this report, Cencora examines how payer perspectives and adoption patterns evolved from 2024 through 2026, highlighting where artificial intelligence is gaining traction, where organizations are seeing measurable value, and which barriers continue to slow broader scale.

Drawing on three years of survey data from healthcare decision-makers, the report explores how managed care organizations are applying artificial intelligence across administrative, analytical, and clinically adjacent workflows. It also examines the growing importance of governance, transparency, system integration, and human oversight as organizations work to adopt artificial intelligence responsibly.

Key highlights

  • AI adoption is progressing from awareness to implementation, with many organizations now scaling beyond pilot programs.
  • Prior authorization is emerging as one of the strongest use cases, particularly in documentation review, clinical decision support, and turnaround time.
  • Administrative operations currently show the broadest measurable value, including improvements in claims processing, reporting, and documentation.
  • AI is expanding into drug utilization review and medication safety, supporting high-risk member identification, drug-drug interaction detection, and alert optimization.
  • Governance remains critical as organizations address data quality, privacy, compliance, explainability, and accountability.
  • Future opportunities are expected to center on more predictive, proactive, and connected workflows across managed care.

Download the white paper

Nous sommes là pour vous aider

Contactez notre équipe dès aujourd’hui pour en savoir plus sur la façon dont Cencora contribue à façonner l’avenir des soins de santé.

Ressources connexes

Article

Rappel à la réalité du CMC : Risques à un stade avancé ayant une incidence sur l’approbation

Livre blanc

La résilience comme avantage concurrentiel
Learn more about 3PL partnerships in the pharma and biopharma landscape

Livre blanc

Réussir dans un paysage pharmaceutique en mutation